August 19, 2009 at 18:50 PM EDT
(AMGN) Mixed Results for Amgen’s Vectibix
Yesterday, Amgen Inc. (AMGN) reported mixed top-line results from a phase III study evaluating Vectibix in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment for metastatic colorectal cancer (mCRC). The trial had two primary endpoints – progression-free and overall survival. Results showed that Vectibix, in combination with FOLFIRI, significantly improved progression-free survival (compared to [...] (AMGN) Mixed Results for Amgen’s Vectibix
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here